Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

Interleukin-1 (IL-1) is a highly active pro-inflammatory cytokine that lowers pain thresholds and damages tissues. Monotherapy blocking IL-1 activity in autoinflammatory syndromes results in a rapid and sustained reduction in disease severity, including reversal of inflammation-mediated loss of sight, hearing and organ function. This approach can therefore be effective in treating common conditions such as post-infarction heart failure, and trials targeting a broad spectrum of new indications are underway. So far, three IL-1-targeted agents have been approved: the IL-1 receptor antagonist anakinra, the soluble decoy receptor rilonacept and the neutralizing monoclonal anti-IL-1β antibody canakinumab. In addition, a monoclonal antibody directed against the IL-1 receptor and a neutralizing anti-IL-1α antibody are in clinical trials.

[1]  C. Dinarello,et al.  Intravitreal Anakinra Inhibits Choroidal Neovascular Membrane Growth in a Rat Model , 2009, Ocular immunology and inflammation.

[2]  J. Sinacore,et al.  Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[3]  Hai Huang,et al.  Administration of interleukin‐1 receptor antagonist ameliorates renal ischemia‐reperfusion injury , 2008, Transplant international : official journal of the European Society for Organ Transplantation.

[4]  J. Singh,et al.  Anakinra for Rheumatoid Arthritis: A Systematic Review , 2009, The Journal of Rheumatology.

[5]  P. Bongrand,et al.  Interleukin-1 induces interleukin-8 secretion from endothelial cells by a juxtacrine mechanism. , 1994, Blood.

[6]  J. D. Edgar,et al.  Etanercept and anakinra can prolong febrile episodes in patients with hyperimmunoglobulin D and periodic fever syndrome , 2009, Rheumatology International.

[7]  K. Scalapino,et al.  Case of anakinra as a steroid-sparing agent for gout inflammation. , 2009, Arthritis and rheumatism.

[8]  S. Özen,et al.  Anti-Interleukin 1 Treatment for Patients with Familial Mediterranean Fever Resistant to Colchicine , 2011, The Journal of Rheumatology.

[9]  B. Bresnihan,et al.  Clinical and radiological effects of anakinra in patients with rheumatoid arthritis. , 2003, Rheumatology.

[10]  M. Donath,et al.  Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes , 2012, Diabetes Care.

[11]  J. Lust,et al.  THE ROLE OF INTERLEUKIN-1β IN THE PATHOGENESIS OF MULTIPLE MYELOMA , 1999 .

[12]  V. Bonagura,et al.  Alternate Splicing of Interleukin-1 Receptor Type II (IL1R2) In Vitro Correlates with Clinical Glucocorticoid Responsiveness in Patients with AIED , 2009, PloS one.

[13]  J. Stockman.  An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist , 2011 .

[14]  B. Giraudeau,et al.  Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. , 2005, The Journal of rheumatology.

[15]  I. Aronson,et al.  Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview , 2010, Dermatologic therapy.

[16]  Charles D. Ellis,et al.  IL-1β receptor antagonist reduces inflammation in hemodialysis patients. , 2011, Journal of the American Society of Nephrology : JASN.

[17]  Leslie L. Chavez,et al.  Topological frustration and the folding of interleukin-1 beta. , 2006, Journal of molecular biology.

[18]  D. Kastner,et al.  Advances in the understanding of familial Mediterranean fever and possibilities for targeted therapy , 2009, British journal of haematology.

[19]  F. Meissner,et al.  Mutant superoxide dismutase 1-induced IL-1β accelerates ALS pathogenesis , 2010, Proceedings of the National Academy of Sciences.

[20]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[21]  B. V. Van Tassell,et al.  Interleukin‐1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse , 2010, European journal of heart failure.

[22]  A. Ventura,et al.  The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever , 2007, European Journal of Pediatrics.

[23]  C. Dinarello,et al.  Interleukin-1 and its relevance in patients treated with hemodialysis. , 1988, Kidney international. Supplement.

[24]  D. Glass,et al.  Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms. , 2008, Arthritis and rheumatism.

[25]  A. So,et al.  Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study , 2011, Arthritis Research & Therapy.

[26]  M. Netea,et al.  Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome , 2005, Annals of the rheumatic diseases.

[27]  F. Martinon,et al.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.

[28]  A. Dispenzieri,et al.  Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.

[29]  T. Valdez,et al.  Do Topical Photoactivated Antimicrobials Cause Ototoxicity? , 2010 .

[30]  C. Dinarello,et al.  Increased plasma interleukin-1 activity in women after ovulation. , 1985, Science.

[31]  P. Hsueh,et al.  Clinical experience of QuantiFERON®‐TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan , 2011, The British journal of dermatology.

[32]  Ian Todd,et al.  Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes , 1999, Cell.

[33]  M. Netea,et al.  Anakinra for the inflammatory complications of chronic granulomatous disease. , 2011, The Netherlands journal of medicine.

[34]  T. Ruzicka,et al.  Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)--a new autoinflammatory syndrome distinct from PAPA syndrome. , 2012, Journal of the American Academy of Dermatology.

[35]  J. V. D. van der Meer,et al.  Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. , 1996, Journal of immunology.

[36]  F. Martinon,et al.  The inflammasomes: guardians of the body. , 2009, Annual review of immunology.

[37]  G. Firestein,et al.  Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist , 2004, The Lancet.

[38]  G. Dannecker,et al.  NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment , 2011, Arthritis research & therapy.

[39]  J. Mier,et al.  Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. , 1992, Cytokine.

[40]  P. Hawkins,et al.  A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. , 2011, Journal of cardiology cases.

[41]  E. Abraham,et al.  Effects of therapy with interleukin-1 receptor antagonist on pulmonary cytokine expression following hemorrhage and resuscitation. , 1994, Lymphokine and cytokine research.

[42]  J. Tschopp,et al.  A pilot study of IL-1 inhibition by anakinra in acute gout , 2007, Arthritis research & therapy.

[43]  J. Stockman.  Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome , 2011 .

[44]  M. Oosting,et al.  Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis. , 2010, Arthritis and rheumatism.

[45]  R. Cron,et al.  Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis with secondary hemophagocytic lymphohistiocytosis. , 2006, The Journal of rheumatology.

[46]  L. Joosten,et al.  Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. , 2004, The American journal of pathology.

[47]  S. Sicherer,et al.  Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition , 2007, Pediatrics.

[48]  J. Peltier,et al.  Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  J. Drenth,et al.  Beneficial response to interleukin 1 receptor antagonist in traps. , 2004, The American journal of medicine.

[50]  M. Watkins.  Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1α , 2012 .

[51]  Seth L Masters,et al.  Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). , 2009, Annual review of immunology.

[52]  L. Cuisset,et al.  Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. , 2008, The Journal of rheumatology.

[53]  R. Goldbach-Mansky.  Current Status of Understanding the Pathogenesis and Management of Patients With NOMID/CINCA , 2011, Current rheumatology reports.

[54]  L. Punzi,et al.  [Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis]. , 2011, Reumatismo.

[55]  C. Dinarello,et al.  Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome. , 2005, Blood.

[56]  Johanne Martel-Pelletier,et al.  Role of proinflammatory cytokines in the pathophysiology of osteoarthritis , 2011, Nature Reviews Rheumatology.

[57]  H. Genant,et al.  FRI0067 Treatment with anakinra reduces the rate of joint destruction and shows accelerated benefit in the second 6 months of treatment for patients with rheumatoid arthritis , 2001 .

[58]  Paul Landais,et al.  Extended Report , 2022 .

[59]  R. Terkeltaub.  Update on gout: new therapeutic strategies and options , 2010, Nature Reviews Rheumatology.

[60]  C. Gabay,et al.  Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. , 2009, Joint, bone, spine : revue du rhumatisme.

[61]  S. Ozen,et al.  Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet’s disease , 2010, Clinical Rheumatology.

[62]  A. Wanderer.  Rationale for IL-1beta targeted therapy for ischemia-reperfusion induced pulmonary and other complications in sickle cell disease. , 2009, Journal of pediatric hematology/oncology.

[63]  R. Cimaz,et al.  Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. , 2010, Clinical and experimental rheumatology.

[64]  L. Kanz,et al.  Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. , 2007, Seminars in arthritis and rheumatism.

[65]  Z Domljan,et al.  Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. , 1998, Arthritis and rheumatism.

[66]  L. Joosten,et al.  The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity , 2009 .

[67]  C. Polman,et al.  Production of IL-1β and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis , 2002, Journal of Neuroimmunology.

[68]  P. Richette,et al.  Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy , 2011, Arthritis research & therapy.

[69]  A. Mantovani,et al.  Cancer-related inflammation: common themes and therapeutic opportunities. , 2012, Seminars in cancer biology.

[70]  E. Keystone,et al.  Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine , 2012, Annals of the rheumatic diseases.

[71]  Stanley B. Cohen,et al.  A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee , 2011, Arthritis research & therapy.

[72]  H. D. de Koning,et al.  Comment on: Schnitzlers syndrome--exacerbation after anti-TNF treatment. , 2007, Rheumatology.

[73]  J. van der Meer,et al.  On-demand anakinra treatment is effective in mevalonate kinase deficiency , 2011, Annals of the rheumatic diseases.

[74]  J. Sikora,et al.  Concentrations of interleukin (IL)-1alpha, IL-1 soluble receptor type II (IL-1 sRII) and IL-1 receptor antagonist (IL-1 Ra) in the peritoneal fluid and serum of infertile women with endometriosis. , 2005, European journal of obstetrics, gynecology, and reproductive biology.

[75]  G. Hitman,et al.  Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. , 2009, Arthritis and rheumatism.

[76]  A. Thatayatikom,et al.  Mutation of a New Gene Encoding a Putative Pyrin-Like Protein Causes Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome , 2002, Pediatrics.

[77]  C. Dinarello.  Anti-inflammatory Agents: Present and Future , 2010, Cell.

[78]  P. White,et al.  Preliminary studies related to anti‐interleukin‐1β therapy in children with newly diagnosed type 1 diabetes , 2011, Pediatric diabetes.

[79]  R. Terkeltaub,et al.  The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study , 2009, Annals of the rheumatic diseases.

[80]  T. Bártfai,et al.  Interleukin‐1 System in CNS Stress , 2007, Annals of the New York Academy of Sciences.

[81]  R. Arena,et al.  Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure , 2012, PloS one.

[82]  M. Uffmann,et al.  Pneumonia in a patient with familial Mediterranean fever successfully treated with anakinra—case report and review , 2012, Rheumatology International.

[83]  A. Plebani,et al.  Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. , 2008, Arthritis and rheumatism.

[84]  J. V. D. van der Meer,et al.  Blocking IL-1β to slow down progression of ALS? , 2010, Proceedings of the National Academy of Sciences.

[85]  P. Hawkins,et al.  Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study , 2011, Arthritis research & therapy.

[86]  S. Schinner.  Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes , 2010 .

[87]  J. Richardson,et al.  Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. , 2013, British journal of clinical pharmacology.

[88]  M. Donath,et al.  Blockade of interleukin 1 in type 1 diabetes mellitus , 2010, Nature Reviews Endocrinology.

[89]  D. Foell,et al.  Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. , 2011, Arthritis and rheumatism.

[90]  C. Bodemer,et al.  Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. , 2010, Arthritis and rheumatism.

[91]  Y. Sharabi,et al.  Differential role and tissue specificity of interleukin-1alpha gene expression in atherogenesis and lipid metabolism. , 2007, Atherosclerosis.

[92]  A. Chakraborty,et al.  Canakinumab (ACZ885, a fully human IgG1 anti-IL-1β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS) , 2011, Arthritis Research & Therapy.

[93]  A. Mirza,et al.  Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study , 2011, Annals of the rheumatic diseases.

[94]  T. Bártfai,et al.  Therapeutic potential of new antiinflammatory drugs , 2011, Epilepsia.

[95]  A. Martini,et al.  Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. , 2007, Arthritis and rheumatism.

[96]  H. Gast,et al.  Inhibition of IL-1β Improves Fatigue in Type 2 Diabetes , 2011, Diabetes Care.

[97]  G. Horneff,et al.  [Improvement of sensoneurinal hearing loss in a patient with Muckle-Wells syndrome treated with anakinra]. , 2010, Klinische Padiatrie.

[98]  A. Oikonomou,et al.  The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis , 2011, Annals of the rheumatic diseases.

[99]  F. Di Virgilio,et al.  Dysregulation of P2X7 receptor-inflammasome axis in SAPHO syndrome: successful treatment with anakinra. , 2010, Rheumatology.

[100]  F. Dewhirst,et al.  Purification and partial sequence of human osteoclast-activating factor: identity with interleukin 1 beta. , 1985, Journal of immunology.

[101]  S. Schreiber,et al.  The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement , 2010, European Respiratory Journal.

[102]  T. Bártfai,et al.  IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures , 2011, Brain, Behavior, and Immunity.

[103]  C. Dinarello,et al.  Biologic basis for interleukin-1 in disease. , 1996, Blood.

[104]  D. Loeuille,et al.  Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. , 2009, Arthritis and rheumatism.

[105]  M. Korppi,et al.  Hyperimmunoglobulinemia D and periodic fever syndrome in children. Review on therapy with biological drugs and case report , 2011, Acta paediatrica.

[106]  J. Sarles,et al.  Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis , 2006, Journal of Inherited Metabolic Disease.

[107]  S. Opal,et al.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. , 1997, Critical care medicine.

[108]  S. Opal,et al.  Initial evaluation of human recombinant interleukin‐1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open‐label, placebocontrolled multicenter trial , 1994, Critical care medicine.

[109]  J. L. F. A. S. Mineishi.  Graft Versus Host Disease , 2005 .

[110]  Dushyant Singh,et al.  IL-1 inhibition with anakinra in a patient with refractory gout. , 2009, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[111]  S. Suissa,et al.  Demyelinating events in rheumatoid arthritis after drug exposures , 2009, Annals of the rheumatic diseases.

[112]  Daniel L. Kastner,et al.  Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS) , 2011, The Journal of experimental medicine.

[113]  M. Dougados,et al.  First observation of the efficacy of IL-1ra to treat tophaceous gout of the lumbar spine. , 2011, Rheumatology.

[114]  Egil Lien,et al.  NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals , 2010, Nature.

[115]  Y. Carmi,et al.  The Role of Macrophage-Derived IL-1 in Induction and Maintenance of Angiogenesis1 , 2009, The Journal of Immunology.

[116]  Andreas Krause,et al.  IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still’s disease , 2010, Annals of the rheumatic diseases.

[117]  G. Burmester,et al.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[118]  M. de Visser,et al.  Complete remission of severe idiopathic cold urticaria on interleukin-1 receptor antagonist (anakinra). , 2009, The Netherlands journal of medicine.

[119]  J. Lekakis,et al.  Inhibition of Interleukin-1 by Anakinra Improves Vascular and Left Ventricular Function in Patients With Rheumatoid Arthritis , 2008, Circulation.

[120]  J. Butman,et al.  Cryopyrin-Associated Periodic Syndromes , 2011, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[121]  U. Broeckel,et al.  An autoinflammatory disease due to homozygous deletion of the IL1RN locus. , 2009, The New England journal of medicine.

[122]  N. Rothwell,et al.  Role of IL-1α and IL-1β in Ischemic Brain Damage , 2001, The Journal of Neuroscience.

[123]  P. Emery,et al.  Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra , 2007, Annals of the rheumatic diseases.

[124]  G. Nishimura,et al.  Effect of anakinra on arthropathy in CINCA/NOMID syndrome , 2010, Pediatric rheumatology online journal.

[125]  R. Blanco,et al.  Successful treatment of refractory Schnitzler syndrome with anakinra: comment on the article by Hawkins et al. , 2005, Arthritis and rheumatism.

[126]  R. F. Johnston,et al.  Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial , 1994 .

[127]  A. Ramanan,et al.  Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). , 2007, Rheumatology.

[128]  V. Pascual,et al.  Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade , 2005, The Journal of experimental medicine.

[129]  A. Dispenzieri,et al.  Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[130]  R. Omdal,et al.  Interleukin-1 Inhibition and Fatigue in Primary Sjögren's Syndrome – A Double Blind, Randomised Clinical Trial , 2012, PloS one.

[131]  A. Martini,et al.  Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. , 2010, The Journal of pediatrics.

[132]  A. François,et al.  Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. , 2010, Joint, bone, spine : revue du rhumatisme.

[133]  N. Wulffraat,et al.  A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. , 2012, Arthritis and rheumatism.

[134]  C. Jorgensen,et al.  Erosive osteoarthritis of the hand: clinical experience with anakinra , 2009, Annals of the rheumatic diseases.

[135]  S. Opal,et al.  Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. , 1994, JAMA.

[136]  Y. Carmi,et al.  IL-1α and IL-1β Recruit Different Myeloid Cells and Promote Different Stages of Sterile Inflammation , 2011, The Journal of Immunology.

[137]  L. Joosten,et al.  Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. , 2011, The Journal of clinical endocrinology and metabolism.

[138]  M. Sone,et al.  Association of interleukin‐1 gene polymorphisms with sudden sensorineural hearing loss and Ménière’s disease , 2011, International journal of immunogenetics.

[139]  R. McIntyre,et al.  IL-1 regulates in vivo C—X—C chemokine induction and neutrophil sequestration following endotoxemia , 2002, Journal of endotoxin research.

[140]  P. Emery,et al.  Successful treatment of resistant pseudogout with anakinra. , 2008, Arthritis and rheumatism.

[141]  D. Kastner,et al.  Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome , 2010, Proceedings of the National Academy of Sciences.

[142]  N. Rothwell,et al.  Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[143]  P. Libby,et al.  Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.

[144]  D. Pisetsky,et al.  The role of microparticles in the pathogenesis of rheumatic diseases , 2010, Nature Reviews Rheumatology.

[145]  Christine E. Becker,et al.  Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes , 2010, Nature Immunology.

[146]  P. McCarthy,et al.  A clinical phase I/II study of recombinant human interleukin-1 receptor in glucocorticoid-resistant graft-versus-host disease. , 1996, Transplantation.

[147]  N. Rothwell,et al.  A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[148]  B. Winblad,et al.  Blunted neurogenesis and gliosis due to transgenic overexpression of human soluble IL‐1ra in the mouse , 2008, The European journal of neuroscience.

[149]  J. Peltola,et al.  Levels of IL-1β and IL-1ra in Cerebrospinal Fluid of Human Patients after Single and Prolonged Seizures , 2009, Neuroimmunomodulation.

[150]  A. Mantovani,et al.  Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. , 1992, Blood.

[151]  Brian J. Smith,et al.  The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[152]  A. Simon,et al.  Hyper-IgD syndrome or mevalonate kinase deficiency , 2011, Current opinion in rheumatology.

[153]  H. Hoffman,et al.  Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[154]  J. Schalkwijk,et al.  Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. , 2011, The Journal of allergy and clinical immunology.

[155]  A. Rissanen,et al.  Effect of anti‐IL‐1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo‐controlled trial , 2012, Diabetes, obesity & metabolism.

[156]  D. Kastner,et al.  The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. , 2001, Blood.

[157]  Y. Carmi,et al.  Differential release of chromatin-bound IL-1α discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation , 2010, Proceedings of the National Academy of Sciences.

[158]  Allan Vaag,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[159]  S. Paul,et al.  Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. , 2012, Arthritis and rheumatism.

[160]  A. Martini,et al.  Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? , 2009, Arthritis and rheumatism.

[161]  G. Pohl,et al.  Successful treatment of familial Mediterranean fever with Anakinra and outcome after renal transplantation. , 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[162]  Harry K Genant,et al.  Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. , 2004, The Journal of rheumatology.

[163]  A. Martini,et al.  The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. , 2008, Arthritis and rheumatism.

[164]  J. Richert,et al.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. , 2001, Arthritis and rheumatism.

[165]  D. Kastner,et al.  Periodic fever, aphthous stomatitis, pharyngitis, and adenitis (PFAPA) is a disorder of innate immunity and Th1 activation responsive to IL-1 blockade , 2011, Proceedings of the National Academy of Sciences.

[166]  D. Kastner,et al.  Autoinflammatory Disease Reloaded: A Clinical Perspective , 2010, Cell.

[167]  N. Wulffraat,et al.  The efficacy and safety of interleukin-1-receptor antagonist anakinra in the treatment of systemic juvenile idiopathic arthritis , 2010, Expert opinion on biological therapy.

[168]  F. Retornaz,et al.  Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. , 2011, Seminars in arthritis and rheumatism.

[169]  P. Libby,et al.  Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. , 1987, Journal of immunology.

[170]  C. Mebus,et al.  Efficacy and Safety of CE-224,535, an Antagonist of P2X7 Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate , 2012, The Journal of Rheumatology.

[171]  C. Dinarello,et al.  Rapid responses to anakinra in patients with refractory adult-onset Still's disease. , 2005, Arthritis and rheumatism.

[172]  Helen J. Lachmann,et al.  In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes , 2009, The Journal of experimental medicine.

[173]  A. So,et al.  Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. , 2010, Arthritis and rheumatism.

[174]  J. Meer,et al.  Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. , 2005, The Netherlands journal of medicine.

[175]  E. Guinan,et al.  Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease , 1994 .

[176]  E. Unanue,et al.  Identification of a membrane-associated interleukin 1 in macrophages. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[177]  B. Bresnihan,et al.  The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. , 2001, Rheumatology.

[178]  C. Dinarello.  Why not treat human cancer with interleukin-1 blockade? , 2010, Cancer and Metastasis Reviews.

[179]  P. Hawkins,et al.  Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes , 2011, Annals of the rheumatic diseases.

[180]  C. Dinarello,et al.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.

[181]  A. So,et al.  Extended Report , 2022 .

[182]  L. Thomsen,et al.  IL-1 beta does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. , 1996, Journal of immunology.

[183]  P. Hawkins,et al.  Systemic amyloidosis , 2016, The Lancet.

[184]  L. Southam,et al.  Functional analysis of the osteoarthritis susceptibility-associated GDF5 regulatory polymorphism. , 2009, Arthritis and rheumatism.

[185]  Y. Tsao,et al.  Therapy and prevention of arthritis by recombinant adeno-associated virus vector with delivery of interleukin-1 receptor antagonist. , 2000, Arthritis and rheumatism.

[186]  R. Kurzrock,et al.  Abstract A211: A phase I study of MABp1, a first-in-human, first-true human monoclonal antibody against the IL-1 in patients with advanced cancers. , 2011 .

[187]  G. Biondi-Zoccai,et al.  Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.

[188]  L. Settas,et al.  Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). , 2007, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[189]  M. Pino,et al.  Phase I/II trial of the type I soluble recombinant human interleukin-1 receptor in HIV-1-infected patients. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[190]  Y. Troyanov,et al.  Macrophage Activation Syndrome Treated with Anakinra , 2010, The Journal of Rheumatology.

[191]  H. Genant,et al.  A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. , 2000, Arthritis and rheumatism.

[192]  P. Itin,et al.  Muckle-Wells Syndrome Effectively Treated with Canakinumab: Is the Recommended Dosing Schedule Mandatory? , 2011, Dermatology.

[193]  G. Biondi-Zoccai,et al.  Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction , 2008, Circulation.

[194]  S. Shoelson,et al.  Type 2 diabetes as an inflammatory disease , 2011, Nature Reviews Immunology.

[195]  Andrea De Gaetano,et al.  Double-Blind, Randomized Study Evaluating the Glycemic and Anti-inflammatory Effects of Subcutaneous LY2189102, a Neutralizing IL-1β Antibody, in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[196]  C. Dinarello,et al.  Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. , 2011, Arthritis and rheumatism.

[197]  S. Al Jumaah,et al.  A retrospective review of autoinflammatory diseases in Saudi children at a rheumatology clinic , 2012, Annals of Saudi medicine.

[198]  J. Gómez-Reino,et al.  Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study , 2011, BMC musculoskeletal disorders.

[199]  J. Sibilia,et al.  Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France , 2007, Annals of the rheumatic diseases.

[200]  J. Drenth,et al.  Long-Term Follow-Up, Clinical Features, and Quality of Life in a Series of 103 Patients With Hyperimmunoglobulinemia D Syndrome , 2008, Medicine.

[201]  G. Yancopoulos,et al.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. , 2008, Arthritis and rheumatism.

[202]  L. Ginsberg,et al.  Neurologic manifestations of the cryopyrin-associated periodic syndrome , 2010, Neurology.

[203]  G. Burmester,et al.  Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. , 2003, Arthritis and rheumatism.

[204]  P. Emery,et al.  Hearing improvement in a patient with variant Muckle-Wells syndrome in response to interleukin 1 receptor antagonism , 2006, Annals of the rheumatic diseases.

[205]  T. Maurer,et al.  Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. , 2010, Archives of dermatology.

[206]  S. Akira,et al.  Identification of a key pathway required for the sterile inflammatory response triggered by dying cells , 2007, Nature Medicine.

[207]  J. G. Ryan,et al.  IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission. , 2008, The Journal of allergy and clinical immunology.

[208]  V. Bonagura,et al.  IL-1β Is Overexpressed and Aberrantly Regulated in Corticosteroid Nonresponders with Autoimmune Inner Ear Disease , 2011, The Journal of Immunology.

[209]  M. Gahr,et al.  Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. , 2011, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[210]  G. Kalliolias,et al.  Anakinra treatment in patients with adult-onset Still’s disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial , 2007, Annals of the rheumatic diseases.